PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025

Reuters

2025/11/10

PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025

PDS Biotechnology Corporation has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute $(NCI)$ Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041286), on November 10, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582743618"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582743618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582743618?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582743618","market":"us","top_or_hot":-1,"title":"PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PDSB\">PDS Biotechnology Corporation</a> has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute <a href=\"https://laohu8.com/S/NCI\">$(NCI)$</a> Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041286), on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 21:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PDSB\">PDS Biotechnology Corporation</a> has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute <a href=\"https://laohu8.com/S/NCI\">$(NCI)$</a> Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041286), on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL73hfZ1:1","article_id":"2582743618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582743618","pubTimestamp":1762781805,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PDS Biotechnology Corporation has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer  Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute  Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PDSB":"PDS Biotechnology Corporation"},"translate_title":"PDS Biotechnology在SITC 2025上报告PDS0101和PDS01ADC的阳性临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PDSB":0.9},"content_text":"PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025\n    \n\nPDS Biotechnology Corporation has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute $(NCI)$ Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041286), on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}